Verana Health has established an Imaging Consortium with leading academic medical centres to integrate ophthalmic images into its real-world data registry. The initiative expands the IRIS Registry Analytics Consortium, founded in 2017, which provides access to data from over 87 million de-identified patients across 12 years. The consortium will incorporate imaging modalities such as Optical Coherence Tomography and fundus photography, essential for diagnosing conditions like diabetic retinopathy, glaucoma and macular degeneration. These images provide detailed, non-invasive views of retinal structures crucial for disease detection and monitoring. Verana Health combines artificial intelligence with physician expertise to analyse ophthalmic images and curate electronic health record data. The company aims to support life sciences companies and clinicians in improving research operations and patient outcomes through enhanced real-world evidence generation.

Verana Health has introduced new urologic-oncology datasets for bladder and prostate cancer research, offering comprehensive longitudinal insights into patient journeys across multiple care settings. The datasets combine data from urology, radiation oncology and medical oncology practices, addressing gaps created when patients transition between specialties. The datasets are powered by Verana Health's recent merger with COTA, which expanded access to over 30 academic medical centres and 10 million oncology patients. The company uses AI and large language models to transform unstructured electronic health record data into research-ready datasets. The bladder cancer dataset includes critical elements like T-stage, tumour focality and grade. The prostate cancer dataset tracks disease evolution through hormone-sensitive, hormone-resistant and metastatic stages. The announcement coincides with the ASCO Genitourinary Cancers Symposium in San Francisco.